利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

190 条记录 (耗时 0.032 秒)

    Drug delivery means
    32.
    发明授权
    Drug delivery means 有权

    公开(公告)号：US11737976B2

    公开(公告)日：2023-08-29

    申请号：US16119931

    申请日：2018-08-31

    申请人： TheraSyn Sensors, Inc.

    发明人： Mary P. McCourt

    IPC分类号： A61K9/127 ,  A61K47/10 ,  A61K47/28 ,  A61K38/17 ,  A61K38/45 ,  A61K38/48

    CPC分类号： A61K9/1272 ,  A61K9/127 ,  A61K9/1277 ,  A61K38/1709 ,  A61K38/1761 ,  A61K38/45 ,  A61K38/482 ,  A61K47/10 ,  A61K47/28 ,  C12Y207/11001 ,  C12Y304/21078 ,  C12Y304/21079

    摘要： The invention broadly comprises a chemical composition including a plurality of cholesteryl esters arranged to form a vesicle. In several embodiments, all of the plurality of cholesteryl esters have a same molecular length, which in some embodiments provides a vesicle having a generally smooth outer surface, while in other embodiments, a portion of the plurality of cholesteryl esters have different molecular lengths, which in some embodiments provides a vesicle having a generally irregular outer surface. In yet further embodiments, a shape of the vesicle is selected from the group consisting of spherical, oval, disc-like, tubular and polyhedral shapes, and in yet other embodiments, a wall of the vesicle is selected from the group consisting of a monolayer and a bilayer. In still further embodiments, the chemical composition further includes a polyethylene glycol coat of mixed polymer size. In some embodiments, the plurality of cholesteryl esters include at least two different cholesteryl esters, and in some of these embodiments, the at least two different cholesteryl esters are selected from the group consisting of cholesteryl myristate, cholesteryl laurate, cholesteryl dodeconate, cholesteryl palmitate, cholesteryl arachidonate, cholesteryl behenate, cholesteryl linoleate, cholesteryl linolenate, cholesteryl oleate and cholesteryl stearate.

    COMPOSITIONS AND METHODS FOR REGULATING ANGIOGENESIS AND CHOLESTEROL AND TREATING DYSLIPIDEMIA, ATHEROSCLEROSIS, CANCER AND INFLAMMATORY CONDITIONS
    40.
    发明申请
    COMPOSITIONS AND METHODS FOR REGULATING ANGIOGENESIS AND CHOLESTEROL AND TREATING DYSLIPIDEMIA, ATHEROSCLEROSIS, CANCER AND INFLAMMATORY CONDITIONS 审中-公开
    用于调节血管生成和胆固醇并治疗氯吡格雷的组合物和方法，ATHEROSCLEROSIS，癌症和炎症条件

    公开(公告)号：US20160115211A1

    公开(公告)日：2016-04-28

    申请号：US14894281

    申请日：2014-05-27

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： Yury MILLER ,  Longhou FANG

    IPC分类号： C07K14/47 ,  C07K16/18 ,  A61K38/17 ,  C12N15/113

    CPC分类号： C07K14/47 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/1761 ,  A61P3/06 ,  A61P29/00 ,  C07K14/4702 ,  C07K16/18 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/3233

    摘要： The invention provides pharmaceutical compounds and formulations comprising nucleic acids and polypeptides for regulating (including upregulating or inhibiting) the expression of ApoA-1 Binding Protein (APOAIBP, AIBP, or AI-BP), and methods for making and using them. In alternative embodiments, APOAIBP-inhibiting pharmaceutical compositions and formulations of the invention are administered to an individual in need thereof in an amount sufficient to stimulate tissue revascularization, e.g., supporting or stimulating revascularization of heart tissue, e.g., after a cardiac ischemia. In alternative embodiments, pharmaceutical compositions and formulations of the invention that comprise APOAIBP nucleic acids and polypeptides or result in an increase in expression or activity of APOAIBP nucleic acids and polypeptides are administered to an individual in need thereof in an amount sufficient to treat, prevent, reverse and/or ameliorate a dyslipidemia, e.g., to treat, prevent, reverse and/or ameliorate conditions responsive to increasing cholesterol efflux from cells, including cardiovascular disease and atherosclerosis.

    摘要翻译： 本发明提供包含用于调节（包括上调或抑制）ApoA-1结合蛋白（APOAIBP，AIBP或AI-BP）表达的核酸和多肽的药物化合物和制剂，以及制备和使用它们的方法。 在替代实施方案中，本发明的APOAIBP抑制药物组合物和制剂以足以刺激组织血运重建的量给予有此需要的个体，例如支持或刺激心脏组织的血运重建，例如在心脏缺血后。 在替代实施方案中，包含APOAIBP核酸和多肽或导致APOAIBP核酸和多肽的表达或活性增加的本发明的药物组合物和制剂以足以治疗，预防， 逆转和/或改善血脂异常，例如，治疗，预防，逆转和/或改善对增加胆固醇从细胞外溢（包括心血管疾病和动脉粥样硬化）的反应。